Factors Influencing Aspirin Hyporesponsiveness in Elderly Chinese Patients

Wei mei Ou
Zhi fang Fu
Xue huan Chen
Xue ru Feng
Hai xia Li
Yao Lu
Mei Liu
Bo Huang
Wen wen Liu
Mei lin Liu

Background: Aspirin hyporesponsiveness increases the risk of ischemic events. Therefore, it is important to investigate the factors influencing aspirin hyporesponsiveness.

Material/Methods: Patients aged 60 years or older who did not take aspirin before enrollment were included, with aspirin 100 mg/day administered after enrollment. The arachidonic acid-induced platelet aggregation rate (Ara) was measured by light transmission assay to evaluate aspirin responsiveness. Patients with Ara in the upper quartile after taking aspirin were assigned to the aspirin hyporesponsive group (Ara-Q4).

Results: A total of 292 elderly patients were included. The median value of Ara after taking aspirin was 5.87% (interquartile range 3.86-10.04%). Compared with the aspirin non-hyporesponsive group (Ara-Q1-3, Ara ≤10.04%, n=220), the level of uric acid (UA) (341.30 µmol/L vs. 299.10 µmol/L, p=0.027) and the ratios of β-blockers (9.72% vs. 2.27%, p=0.015) and diuretics (6.94% vs. 1.36%, p=0.036) were higher in the aspirin hyporesponsive group (Ara-Q4, Ara >10.04%, n=72). After multivariate adjustment, the results demonstrated baseline Ara (odds ratio [OR]: 1.030, 95% confidence interval [CI]: 1.004–1.056, p=0.021), UA level (OR: 1.003, 95% CI: 1.000–1.006, p=0.036), and β-blockers use (OR: 5.487, 95% CI: 1.515–19.870, p=0.010) were independently and positively associated with aspirin hyporesponsiveness.

Conclusions: This study found that baseline Ara, UA level, and β-blockers use were independently and positively associated with aspirin hyporesponsiveness in elderly Chinese patients, which needs to be validated in large-scale studies.

MeSH Keywords: Aspirin • Frail Elderly • Platelet Aggregation Inhibitors

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/917654
Background

With the rapid increase of the elderly population, cardiovascular diseases have become the primary threat to human life and health. Studies have well documented that aspirin can significantly reduce major adverse cardiovascular events (MACE) through irreversible inhibition of platelet aggregation [1,2]. However, there are still numerous patients suffering from MACE despite being on regular aspirin therapy [3,4], which is associated with aspirin hyporesponsiveness.

Aspirin hyporesponsiveness, also called high on-aspirin platelet reactivity, is defined as incomplete inhibition of platelet aggregation after taking aspirin. To date, there is still no consensus on the cut-off value of aspirin hyporesponsiveness [4–7]. Studies have demonstrated that aspirin hyporesponsiveness increases the risk of ischemic events [8,9]. Therefore, it is of great significance to investigate the factors influencing aspirin hyporesponsiveness, which could help to identify patients at a high risk of ischemic events. However, relevant data on elderly patients are scarce, particularly in China. Consequently, this study investigated potential factors influencing aspirin hyporesponsiveness in elderly Chinese patients.

Material and Methods

Patient selection

From September 2016 to December 2016, patients aged 60 years or older from 18 hospitals in China who did not take aspirin before enrollment were included (No. ChiCTR1800018517). The inclusion criteria were: (1) age 60 years or older; (2) regularly took aspirin 100 mg/day at least 7 days after enrollment; (3) patients who took aspirin for primary prevention had to have 1) at least 1 of these 3 diseases: hypertension, diabetes mellitus (DM), and dyslipidemia; or 2) at least 2 of the following conditions: smoking, body mass index (BMI) ≥28.00 kg/m², and family history of premature cardiovascular diseases (men <55 years, women <65 years); (4) patients who took aspirin for secondary prevention had to have at least 1 of the following diseases: 1) stable clinically diagnosed-coronary heart disease; and 2) stable stent-implantation in coronary artery for more than 1 year with aspirin monotherapy.

The exclusion criteria were: (1) allergy or contraindication of aspirin; (2) at a high risk of bleeding, such as erosive gastritis, peptic ulcer, history of gastrointestinal or intracranial hemorrhage; (3) platelet count <80×10⁹/L or >500×10⁹/L; (4) concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), other antiplatelet medications, glycoprotein IIb/IIIa receptor inhibitors, vitamin K antagonists, or novel anticoagulants; (5) left main coronary artery diseases or severe 3-vessel diseases; and (6) other unsuitable patients such as those with malignant tumor, severe liver dysfunction, or severe renal dysfunction.

The study was carried out in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Review Committee of Peking University First Hospital (No. 2016[1175]). Written informed consent was obtained from all participants.

Medical records collection

For each patient, detailed medical records on enrollment were collected, including demographic information, comorbidities, concomitant medications, and baseline biological parameters.

Light transmission assay

To evaluate aspirin responsiveness (before and after taking aspirin), 0.50 mg/mL arachidonic acid-induced platelet aggregation rate (Ara) was measured by light transmission assay (LTA) using LBY-NJ4 platelet aggregometer (PRECiL, Beijing, China), as described previously [5].

Patient group

Patients with Ara in the upper quartile after taking aspirin (Ara-Q4) were defined as the aspirin hyporesponsive group, whereas patients with Ara below the upper quartile after taking aspirin (Ara-Q1-3) were defined as the aspirin non-hyporesponsive group [5].

Subgroup studies were conducted by age (≥80 years or not), bodyweight (≥70 kg or not), BMI (≥28.00 kg/m² or not), and smoking amount (≥20 pack-years or not).

The cut-off value of hyperuricemia in the elderly was defined as uric acid (UA) concentration >416.50 µmol/L (7 mg/dL) in men and >357.00 µmol/L (6 mg/dL) in women [10].

Statistical analysis

Conformity to normal distribution was evaluated for continuous variables using the Kolmogorov-Smirnov test. Continuous variables were described as mean ±SD or median (interquartile range, IQR), whereas categorical variables were described as frequency (percent). The independent t test or nonparametric Mann-Whitney U test was used to compare continuous variables, whereas chi-square or Fisher exact test was applied for categorical variables. Spearman’s correlation analysis was used to assess the correlation between influencing factors and aspirin hyporesponsiveness. Binary logistic regression analysis was performed to adjust multivariate factors of aspirin hyporesponsiveness. Receiver operating characteristic curve (ROC) analysis was used to evaluate the predictive value of potential factors influencing aspirin hyporesponsiveness.
influencing factors. A 2-tailed p-value < 0.05 was statistically significant. Statistical analysis was carried out using SPSS version 22.0 software (SPSS, Inc., Chicago, IL, USA). The flowchart of the study is shown in Figure 1.

Results

Enrollment

A total of 292 elderly patients (age range 60–88 years) were included. The average age was 66.51±6.05 years, and 116 (39.73%) patients were males. There were 13 (4.45%) patients with age ≥80 years, 111 (38.01%) patients with bodyweight ≥70 kg, and 31 (10.62%) patients with BMI ≥28.00 kg/m². Among the 50 (17.12%) smoking patients, 34 (68.00%) smoked ≥20 pack-years. Comorbidities and concomitant medications are shown in Table 1.

Distribution of platelet aggregation rate

The range of baseline Ara was from 44.94% to 100.00%, with a median value of 82.62% (IQR 72.55%-89.28%). The range of decrease in Ara after taking aspirin was from 30.06% to 97.24%, with a median value of 74.18% (IQR 64.44–81.68%). The range of Ara after taking aspirin was from 1.01% to 43.51%, with a median value of 5.87% (IQR 3.86–10.04%).

Table 1. Clinical data of all patients.

| Patients (n=292) |       |
|-----------------|-------|
| Age, years      | 66.51±6.05 |
| 60–79 years, n (%) | 279 (95.55) |
| ≥80 years, n (%)  | 13 (4.45)  |
| Sex             |       |
| Male, n (%)     | 116 (39.73) |
| Female, n (%)   | 176 (60.27) |
| Body weight     |       |
| <70 kg, n (%)   | 181 (61.99) |
| ≥70 kg, n (%)   | 111 (38.01) |
| BMI             |       |
| <28.00 kg/m², n (%) | 261 (89.38) |
| ≥28.00 kg/m², n (%) | 31 (10.62) |
| Smoking amount (n=145) |       |
| <20 pack-years, n (%) | 16 (32.00) |
| ≥20 pack-years, n (%) | 34 (68.00) |
| Comorbidities   |       |
| Hypertension, n (%) | 201 (68.84) |
| DM, n (%)       | 65 (22.26) |
| Dyslipidemia, n (%) | 146 (50.00) |
| CHD, n (%)      | 20 (6.85) |
| PCI, n (%)      | 4 (1.37) |
| Concomitant medications |       |
| Statins, n (%)  | 32 (10.96) |
| ACEI, n (%)     | 20 (6.85) |
| ARB, n (%)      | 32 (10.96) |
| β-blockers, n (%) | 12 (4.11) |
| CCB, n (%)      | 94 (32.19) |
| Diuretics, n (%) | 8 (2.74) |
| Nitrates, n (%) | 2 (0.68) |
| Hypoglycemics, n (%) | 38 (13.01) |
| PPI, n (%)      | 1 (0.34) |

BMI – body mass index; DM – diabetes mellitus; CHD – coronary heart diseases; PCI – percutaneous coronary intervention; ACEI – angiotensin-converting enzyme inhibitors; ARB – angiotensin receptor blockers; CCB – calcium channel blockers; PPI – proton pump inhibitors.

Spearman’s correlation analysis showed the extent of decrease in Ara after taking aspirin was positively correlated with age.
There were no significant correlations between the extent of decrease in Ara after taking aspirin and bodyweight (r=–0.079, p=0.177), BMI (r=–0.017, p=0.774), or smoking amount (r=0.127, p=0.379), as shown in Table 2.

There were 15 (5.14%) patients with Ara >20%. According to the aforementioned definition, there were 72 patients in the aspirin hyporesponsive group (Ara-Q4, Ara >10.04%), with a median value of 14.28% (IQR 11.63%-18.49%), and there were 220 patients in the aspirin non-hyporesponsive group (Ara-Q1-3, Ara ≤10.04%), with a median value of 4.85% (IQR 3.26–6.56%). The distribution of Ara is shown in Figure 2.

Clinical features of aspirin hyporesponsive group

We compared patients’ demographics, comorbidities, biological parameters, and concomitant medications between the aspirin hyporesponsive group (Ara-Q4) and the aspirin non-hyporesponsive group (Ara-Q1-3), as shown in Table 3. Compared with the aspirin non-hyporesponsive group (Ara-Q1-3), the level of UA (341.30 µmol/L vs. 299.10 µmol/L, p=0.027), and the ratios of β-blockers use (9.72% vs. 2.27%, p=0.015) and diuretics use (6.94% vs. 1.36%, p=0.036) were higher in the aspirin hyporesponsive group (Ara-Q4).

There were no significant differences in age ≥80 years (4/72, 5.56% vs. 9/220, 4.09%, p=0.846), bodyweight ≥70 kg (32/72, 44.44% vs. 79/220, 35.91%, p=0.195), BMI ≥28 kg/m² (11/72, 15.28% vs. 20/220, 9.09%, p=0.139), and smoking amount ≥20 pack-years (11/13, 84.62% vs. 23/37, 62.16%, p=0.251) between the aspirin hyporesponsive group (Ara-Q4) and the aspirin non-hyporesponsive group (Ara-Q1-3), as shown in Figure 3.

Compared with the aspirin non-hyporesponsive group (Ara-Q1-3), the incidence of hyperuricemia was higher in the aspirin hyporesponsive group (Ara-Q4) (23/69, 33.33% vs. 43/212, 20.28%, p=0.026), as shown in Figure 4.

Factors influencing aspirin hyporesponsiveness

Spearman’s correlation analysis was performed to evaluate the correlation between aspirin hyporesponsiveness and those variables with a p-value <0.05 in Table 3 (UA, β-blockers, and diuretics). The results showed that the level of UA (r=0.132, p=0.027), use of β-blockers (r=0.162, p=0.006), and use of diuretics (r=0.147, p=0.012) were positively correlated with aspirin hyporesponsiveness (Table 4).

Binary logistic regression analysis was performed for multivariate adjustment. Age, sex, and variables listed in Table 3 with a p-value <0.10 (baseline Ara, triglyceride, UA, statins, β-blockers, diuretics) were selected. The results revealed that baseline Ara (odds ratio [OR]: 1.030, 95% CI: 1.004–1.056, p=0.021), UA level (OR: 1.003, 95% CI: 1.000–1.006, p=0.038) and β-blockers use (OR: 5.487, 95% CI: 1.515–19.870, p=0.010) were independently and positively associated with aspirin hyporesponsiveness (Table 5).

Receiver operating characteristic (ROC) curve analysis were used to assess the predictive value of variables with a p-value <0.05 in Table 5 (baseline Ara, UA, and β-blockers). The results showed that the area under the curve (AUC) of the UA level was 0.588 (95% CI: 0.508–0.669, p=0.027), as shown in Table 6.
To date, there is still no consensus on the definition of aspirin hyporesponsiveness, mainly because various methods are used to evaluate aspirin responsiveness, and there is no universally accepted cut-off value of each method used to define aspirin hyporesponsiveness [5,11,12]. In this study, LTA was used to assess aspirin responsiveness and Ara located in the upper quartile after taking aspirin (Ara-Q4) were defined as aspirin hyporesponsiveness [5].

Aspirin hyporesponsiveness increases the risk of ischemic events [13, 14]. Therefore, it is important to investigate the factors influencing aspirin hyporesponsiveness. Dillinger et al. demonstrated DM and age were predictors of aspirin hyporesponsiveness [15]. Wang et al. found hypertension and DM were relative risk factors of aspirin hyporesponsiveness [16]. Both Capone et al. and Catella-Lawson et al. reported that concomitant administration of NSAIDs interfered with the inhibitory effect of aspirin [17,18]. However, relevant data in the elderly population are scant. The present study investigated the factors influencing aspirin hyporesponsiveness in elderly Chinese patients.

Advanced age is associated with high risk of ischemic events, which might be partly due to an increased incidence of aspirin hyporesponsiveness in this population [15,19]. In our study, a
### Table 3. Clinical features of different aspirin responsiveness groups.

|                                | Aspirin hyporesponsive group (Ara-Q4, n=72) | Aspirin non-hyporesponsive group (Ara-Q1-3, n=220) | P-value |
|--------------------------------|--------------------------------------------|--------------------------------------------------|---------|
| **Patients' demographics**     |                                            |                                                  |         |
| Age (years)                    | 64 (62–67)                                 | 66 (62–70)                                       | 0.139   |
| Male, n (%)                    | 32 (44.44)                                 | 84 (38.18)                                       | 0.346   |
| Bodyweight (kg)                | 68 (60–74)                                 | 65 (60–71)                                       | 0.239   |
| BMI (kg/m²)                    | 24.22 (22.46–26.34)                        | 24.05 (22.86–26.02)                             | 0.747   |
| Smoking, n (%)                 | 13 (18.06)                                 | 37 (16.82)                                       | 0.809   |
| Drinking, n (%)                | 18 (25.00)                                 | 42 (19.09)                                       | 0.281   |
| **Comorbidities**              |                                            |                                                  |         |
| Hypertension, n (%)            | 53 (73.61)                                 | 148 (67.27)                                      | 0.313   |
| DM, n (%)                      | 17 (23.61)                                 | 48 (21.82)                                       | 0.751   |
| Dyslipidemia, n (%)            | 37 (51.39)                                 | 109 (49.55)                                      | 0.786   |
| CHD, n (%)                     | 6 (8.33)                                   | 14 (6.36)                                        | 0.760   |
| PCI, n (%)                     | 1 (1.39)                                   | 3 (1.36)                                         | > 0.999 |
| **Biological parameters**      |                                            |                                                  |         |
| Baseline Ara (%)               | 84.67 (73.67–90.44)                        | 81.47 (71.76–88.63)                             | 0.095#  |
| WBC (×10⁹/L)                   | 5.77 (4.92–6.77)                           | 5.92 (4.93–6.76)                                | 0.506   |
| RBC (×10¹²/L)                  | 4.63±0.48                                  | 4.63±0.45                                       | 0.973   |
| Hb (g/L)                       | 139.78±15.13                               | 140.25±13.29                                    | 0.803   |
| PLT (×10⁹/L)                   | 221.13±52.74                               | 213.84±51.03                                    | 0.298   |
| MPV (fl)                       | 9.98±1.29                                  | 9.90±1.31                                       | 0.655   |
| ALT > 40 IU/L, n (%)           | 2 (2.78)                                   | 17 (7.73)                                        | 0.238   |
| AST > 40 IU/L, n (%)           | 1 (1.39)                                   | 8 (3.64)                                         | 0.568   |
| TG (mmol/L)                    | 1.33 (0.93–1.97)                           | 1.56 (1.15–1.98)                                | 0.085#  |
| TC (mmol/L)                    | 5.11±1.00                                  | 5.14±1.12                                       | 0.842   |
| LDL-C (mmol/L)                 | 3.05 (2.45–3.79)                           | 3.05 (2.47–3.71)                                | 0.929   |
| HDL-C (mmol/L)                 | 1.37 (1.18–1.58)                           | 1.40 (1.20–1.61)                                | 0.493   |
| UA (μmol/L)                    | 341.30 (256.80–420.20)                     | 299.10 (247.30–364.38)                          | 0.027*  |
| CCR (mL/min)                   | 81.25±22.93                                | 81.01±21.95                                     | 0.937   |
| GLU (mmol/L)                   | 5.39 (4.95–6.06)                           | 5.43 (5.03–6.25)                                | 0.486   |
| Urine protein, n (%)           | 7 (9.72)                                   | 16 (7.27)                                        | 0.510   |
| Occult blood, n (%)            | 1 (1.39)                                   | 2 (0.91)                                         | > 0.999 |
| **Concomitant medications**    |                                            |                                                  |         |
| Statins, n (%)                 | 12 (16.67)                                 | 20 (9.09)                                        | 0.074#  |
| ACEI, n (%)                    | 4 (5.56)                                   | 16 (7.27)                                        | 0.617   |
| ARB, n (%)                     | 8 (11.11)                                  | 24 (10.91)                                       | 0.962   |
| β-blockers, n (%)              | 7 (9.72)                                   | 5 (2.27)                                         | 0.015*  |
Table 3 continued. Clinical features of different aspirin responsiveness groups.

|                          | Aspirin hyporesponsive group (Ara-Q4, n=72) | Aspirin non-hyporesponsive group (Ara-Q1-3, n=220) | P-value |
|--------------------------|---------------------------------------------|-----------------------------------------------|---------|
| CCB, n (%                | 26 (36.11)                                  | 68 (30.91)                                    | 0.412   |
| Diuretics, n (%)         | 5 (6.94)                                     | 3 (1.36)                                      | 0.036*  |
| Nitrates, n (%)          | 0 (0)                                        | 2 (0.91)                                      | >0.999  |
| Hypoglycemics, n (%)     | 7 (9.72)                                     | 31 (14.09)                                    | 0.339   |
| PPI, n (%)               | 0 (0)                                        | 1 (0.45)                                      | >0.999  |

Continuous variables are described as mean ±SD or median (interquartile range), whereas categorical variables are described as frequency (percent). * p<0.10, * p<0.05 BMI – body mass index; DM – diabetes mellitus; CHD – coronary heart diseases; PCI – percutaneous coronary intervention; Ara – arachidonic acid-induced platelet aggregation rate; WBC – white blood cell; RBC – red blood cell; Hb – hemoglobin; PLT – platelet; MPV – mean platelet volume; ALT – alanine aminotransferase; AST – aspartate transaminase; TG – triglyceride; TC – total cholesterol; LDL-C – low density lipoprotein cholesterol; HDL-C – high-density lipoprotein cholesterol; UA – uric acid; CCR – creatinine clearance rate (according to Cockcroft formula); GLU – glucose; ACEI – angiotensin-converting enzyme inhibitors; ARB – angiotensin receptor blockers; CCB – calcium channel blockers; PPI – proton pump inhibitors.

Table 4. The correlation between aspirin hyporesponsiveness and potential influencing factors.

| Spearman’s rho Aspirin hyporesponsiveness Correlation coefficient | UA | β-blockers | Diuretics |
|------------------------------------------------------------------|----|------------|-----------|
| Spearman’s rho Aspirin hyporesponsiveness Correlation coefficient | 0.132 | 0.162 | 0.147 |
| P-value                                                          | 0.027* | 0.006* | 0.012* |
| N                                                                | 281 | 292 | 292 |

* p<0.05. UA – uric acid.

Table 5. The potential factors influencing aspirin hyporesponsiveness.

|                     | B   | SE  | Wald  | P-value | OR   | 95% lower | 95% upper |
|---------------------|-----|-----|-------|---------|------|-----------|-----------|
| Age                 | -0.050 | 0.026 | 3.568 | 0.059 | 0.951 | 0.904 | 1.002 |
| Baseline Ara        | 0.029 | 0.013 | 5.311 | 0.021* | 1.030 | 1.004 | 1.056 |
| UA                  | 0.003 | 0.002 | 4.319 | 0.038* | 1.003 | 1.000 | 1.006 |
| Statins             | 0.717 | 0.430 | 2.778 | 0.096 | 2.049 | 0.881 | 4.762 |
| β-blockers          | 1.702 | 0.657 | 6.722 | 0.010* | 5.487 | 1.515 | 19.870 |
| Constant            | -1.448 | 1.968 | 0.541 | 0.462 | 0.235 |

* p<0.05. Ara – arachidonic acid-induced platelet aggregation rate; UA – uric acid; SE – standard error; OR – odds ratio

Table 6. The predictive value of potential influencing factors for aspirin hyporesponsiveness.

|                     | AUC | SE  | P-value | 95% lower | 95% upper |
|---------------------|-----|-----|---------|-----------|-----------|
| Baseline Ara        | 0.569 | 0.039 | 0.085 | 0.493 | 0.645 |
| UA                  | 0.588 | 0.041 | 0.027* | 0.508 | 0.669 |
| β-blockers          | 0.539 | 0.041 | 0.331 | 0.458 | 0.620 |

* p<0.05. Ara – arachidonic acid-induced platelet aggregation rate; UA – uric acid; AUC – area under the curve; SE – standard error.
total of 292 elderly patients from 18 hospitals in China were included, which was somewhat representative of all elderly Chinese patients. There was an obvious decrease in Ara after taking aspirin. The extent of decrease in Ara after taking aspirin was positively correlated with age (r=0.145, p=0.013). However, the proportion of patients age ≥80 years in the aspirin hyporesponsive group (Ara-Q4) was not significantly different from that of the aspirin non-hyporesponsive group (Ara-Q1-3) (4/72, 5.56% vs. 9/220, 4.09%, p=0.846), probably because the number of patients age ≥80 years in each group was too small to show statistical power. Further large-scale clinical trials involving elderly patients are needed.

A recent study found that low-dose aspirin (75–100 mg) was effective in preventing cardiovascular events in participants weighting 50–69 kg, but was less effective in participants weighing 70 kg or more [20], suggesting that the administration of aspirin should be individualized depending on bodyweight. Golukhova et al. found BMI was an independent predictor of future aspirin hyporesponsiveness (OR: 1.003, 95% CI: 1.000–1.006, p=0.030) [21]. In this study, there were no significant differences in bodyweight ≥70 kg (32/72, 44.44% vs. 79/220, 35.91%, p=0.195) or BMI ≥28 kg/m² (11/72, 15.28% vs. 20/220, 9.09%, p=0.139) between the aspirin hyporesponsive group (Ara-Q4) and the aspirin non-hyporesponsive group (Ara-Q1-3), which might be due to race, age, and the small scale of the study.

Kaplon-Cieślicka et al. found smoking was an independent predictor of aspirin hyporesponsiveness (OR: 3.891, 95% CI: 1.052–14.391, p=0.042) [22]. In the present study, the proportions of smoking (13/72, 18.06% vs. 37/220, 16.82%, p=0.809) and smoking amount ≥20 pack-years (11/13, 84.62% vs. 23/37, 62.16%, p=0.251) in the aspirin hyporesponsive group (Ara-Q4) were not significantly different from the aspirin non-hyporesponsive group (Ara-Q1-3). A possible explanation is that the scale of the study was too small to show statistical power, and this topic warrants further investigation in large-scale studies.

In this study, the level of UA and the incidence of hyperuricemia were higher in the aspirin hyporesponsive group (Ara-Q4) than that in the aspirin non-hyporesponsive group (Ara-Q1-3). Spearman's correlation analysis showed that the level of UA was positively correlated with aspirin hyporesponsiveness (r=0.132, p=0.027). After multivariate adjustment, the results demonstrated the level of UA was independently and positively associated with aspirin hyporesponsiveness (OR: 1.003, 95% CI: 1.000–1.006, p=0.038), suggesting that increased UA level increases the risk of aspirin hyporesponsiveness. This is consistent with a previous study showing that the level of UA was an independent predictor of aspirin hyporesponsiveness (OR: 1.004, 95% CI: 1.000–1.007, p=0.048) [5]. A possible explanation is that the elevation of UA level promoted formation of a proinflammatory and prothrombotic state, with an increase in non-platelet-derived thromboxane A2 synthesis, leading to increased platelet aggregation and aspirin hyporesponsiveness [23]. ROC curve analysis demonstrated that UA level has limited predictive value for aspirin hyporesponsiveness (AUC: 0.588, 95% CI: 0.508–0.669, p=0.027), which might be related to the small scale of the study, and further validation in large-scale randomized controlled trials (RCT) is warranted.

Drug-drug interactions can affect the response to aspirin [24–26]. Bonten et al. found β-blockers significantly reduced platelet aggregation, which was synergistic with the response to aspirin [27], whereas Knight et al. found β-blockers enhanced platelet aggregation, which was antagonistic to the response to aspirin [28]. At present, there is still no consensus on the correlation between β-blockers and aspirin responsiveness. In this study, compared with the aspirin non-hyporesponsive group (Ara-Q1-3), the proportion of β-blockers use was significantly higher in the aspirin hyporesponsive group (Ara-Q4) (7/72, 9.72% vs. 5/220, 2.27%, p=0.015). Spearman's correlation analysis showed the use of β-blockers was positively correlated with aspirin hyporesponsiveness (r=0.162, p=0.006). Multivariate regression analysis demonstrated the use of β-blockers was independently and positively associated with aspirin hyporesponsiveness (OR: 5.487, 95% CI: 1.515–19.870, p=0.010). However, ROC curve analysis failed to show the value of β-blockers use for predicting aspirin hyporesponsiveness (AUC: 0.539, 95% CI: 0.458–0.620, p=0.331). It did not rule out the possibility that the scale of the study too small to achieve statistical significance, and this topic should be investigated further in large-scale clinical trials.

In this study, the ratio of diuretics use was higher in the aspirin hyporesponsive group (Ara-Q4) than in the aspirin non-hyporesponsive group (Ara-Q1-3) (5/72, 6.94% vs. 23/37, 62.16%, p=0.036), which is consistent with a previous study [5]. A possible mechanism is that diuretics use decreased the glomerular filtration rate [29], resulting in accumulation of harmful substances and increase of non-platelet-derived thromboxane A2 synthesis, which could lead to aspirin hyporesponsiveness. However, diuretics use was not entered into the regression equation after multivariate adjustment, perhaps because the number of patients using diuretics in this study was too small.

The strengths of this study are: (1) The studied elderly patients were included from nationwide hospitals, which is somewhat representative of all elderly Chinese patients; (2) Patients with aspirin monotherapy were included in this study, excluding the interference of other antithrombotic and antiplatelet medications on aspirin responsiveness; and (3) The main findings of this study were that baseline Ara, UA level, and β-blockers use were independently and positively associated with aspirin hyporesponsiveness. Large-scale RCTs are needed to further investigate this.
The weaknesses of this study are: (1) The scale of this study was small, which might have affected the statistical power; (2) The number of patients age ≥80 years was small, which might have biased our results; and (3) The underlying mechanisms of potential factors influencing aspirin hyporesponsiveness were unclear and need to be investigated in large-scale RCTs.

Conclusions

This study found that: (1) the decreasing extent of Ara after taking aspirin was positively correlated with age; (2) baseline Ara, UA level, and ß-blockers use were independently and positively associated with aspirin hyporesponsiveness in elderly Chinese patients. Our results need to be confirmed in large-scale clinical trials.

Acknowledgments

We sincerely thank the following clinicians from 17 other hospitals for their kind support in this study: 1. Department of Neurology, Zhuzhou City 331 Hospital, Zhuzhou, Hunan: Mingfang Qin, Zhiwei He, Yanli Liao; 2. Department of Internal Medicine, Chifeng City Songshan District Hospital, Chifeng, Inner Mongolia: Yanmei Sun, Yanyan Zhao; 3. Department of Geriatrics, Linyi People’s Hospital, Linyi, Shandong: Tao Tian, Xia Chen; 4. Department of Cardiology, Shandong Energy Zibo Mining Group Co. Ltd Central Hospital, Zibo, Shandong: Jingqiao Li, Guizhen Shi; 5. Department of Geriatrics, Binzhou Medical University Hospital, Binzhou, Shandong; 6. Department of Internal Medicine, Jincheng Coal Industry Group Fenghuangshan Mining Hospital, Jincheng, Shanxi: Jun Li, Yuefang QJ; 7. Department of Geriatrics, The Affiliated Hospital of Qingdao University, Qingdao, Shandong: Yongjun Mao, Song Hu; 8. Department of Cardiology, The 5th People’s Hospital of Ji’nan, Jinan, Shandong: Zhisheng Jia, Huailing Su; 9. Department of Encephalopathy, Xiang Yang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei: Zhiyong Fang, Fengping Wang, Zhen Li; 10. Department of Internal Medicine, Wuyi Country People’s Hospital, Hengshui, Hebei: Zhiping Lv, Hongyan Miao; 11. Department of Neurology, Chinese PLA 401 Hospital, Qingdao, Shandong: Lianqiu Cui, Wenjing Li; 12. Department of Cardiology, The 8th People’s Hospital of Zibo, Zibo, Shandong: Chunhui Gao, Wen Zhang; 13. Department of Geriatrics, Daqing Oilfield General Hospital, Daqing, Heilongjiang: Lina Wang; 14. Department of Cardiology, Peking University First Hospital Fengtai Hospital, Beijing: Yongming Hui, Ning Yu, Qiaomei Yang; 15. Department of Geriatrics, Qilu Hospital of Shandong University, Jinan, Shandong: Peiyuan Shan, Lin Ma, Yan Lin; 16. Department of Cardiology, Taiyuan City Central Hospital, Taiyuan, Shanxi: Xiaoping Chen, Zhihua Fu, Lijuan Huo; 17 Department of Cardiology, PKUCare Luzhong Hospital, Zibo, Shandong: Pengfei Yin, Hui Zhou.

Conflict of interest

None.

References:

1. Xian Y, Wang TY, McCoy LA et al: Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with adp receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSALTE-ACS) study. Circulation, 2015; 132: 174–81.
2. Raju N, Sobieraj-Teague M, Hirsh J et al: Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med, 2011; 124: 621–29.
3. Filolaki A, Katsanos AH, Kyritsis AP et al: High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. J Neurol Sci, 2017; 376: 112–16.
4. Gori AM, Grifoni E, Valenti R et al: High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. Eur J Intern Med, 2016; 30: 49–54.
5. Zhang JW, Liu WW, Mccaffrey TA et al: Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. Clin Interv Aging, 2017; 12: 1271–79.
6. Breet NJ, van Werkum JW, Bouman HJ et al: High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart, 2011; 97: 983–90.
7. Yeo KK, Armstrong EI, Lopez JE et al: Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. Cathero Cardiol Interv, 2018; 91: 1308–17.
8. Zhang J, Gao X, Ge Z et al: High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention. BMC Cardiovasc Disord, 2016;16: 240.
9. Oh MS, Yu KH, Lee JH et al: Aspirin resistance is associated with increased stroke severity and infarct volume. Neurology, 2016; 86: 1808–17.
10. Choi H, Kim HC, Song BM et al: Serum uric acid concentration and metabolic syndrome among elderly Koreans: The Korean Urban Rural Elderly (KURE) study. Arch Gerontol Geriatr, 2016; 64: 51–58.
11. Blann AD, Kuzniatsova N, Velu S, Lip GYH: Renal function and aspirin resistance in patients with coronary artery disease. Thromb Res, 2012; 130: e103–e6.
12. Pettersen AA, Arnesen H, Seljeflot I: A brief review on high on-aspirin residual platelet reactivity. Vascul Pharmacol, 2015; 67–69: 6–9.
13. Mayer K, Bernlochner I, Braun S et al: Aspirin treatment and outcomes after percutaneous coronary intervention: Results of the ISAR-ASPI registry. J Am Coll Cardiol, 2014; 64: 863–71.
14. Wismann PP, Roest M, Asselbergs FW et al: Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: A systematic review and meta-analysis. J Thromb Haemost, 2014; 12: 736–47.
15. Dillingen IG, Saeed A, Spagnoli V et al: High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. Thromb Res, 2016; 144: 56–61.
16. Wang CB, Hu DY, Shi XB et al: [Aspirin resistance in patients taking small dose of aspirin]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 2006; 18: 219–23 [in Chinese].
17. Capone ML, Sciuilli MG, Tacconelli S et al: Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol, 2005; 45: 1295–301.
18. Catella-Lawson F, Reilly MP, Kapoor SC et al: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001; 345: 1809–17.
19. Verdolai M, De Luca G: Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor: reply. J Thromb Haemost, 2016; 14: 1486–8.

20. Rothwell PM, Cook NR, Gaziano JM et al: Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials. Lancet, 2018; 392: 387–99.

21. Golukhova EZ, Grigoryan MV, Ryabinina MN et al: Body mass index and plasma P-Selectin before coronary stenting predict high residual platelet reactivity at 6 months on dual antiplatelet therapy. Cardiology, 2018; 139: 132–36.

22. Kapłon-Cieślicka A, Rosiak M, Postula M et al: Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol, 2013; 71: 893–902.

23. Zapolski T, Wacinski P, Kondracki B et al: Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiol Pol, 2011; 69: 319–26.

24. Feher G, Koltai K, Papp E et al: Aspirin resistance: Possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorheological variables. Drugs Aging, 2006; 23: 559–67.

25. Al-Azzam SI, Alzoubi KH, Khabour OF et al: Evaluation of the effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on aspirin antiplatelet effect. Int J Clin Pharmacol Ther, 2016; 54: 96–101.

26. Andersson T, Morrison D, Nagy P et al: Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. Am J Cardiovasc Drugs, 2012; 12: 217–24.

27. Bonten TN, Plaizier CE, Snoep JJ et al: Effect of beta-blockers on platelet aggregation: A systematic review and meta-analysis. Br J Clin Pharmacol, 2014; 78: 940–49.

28. Knight CJ, Panesar M, Wilson DJ et al: Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation, 1997; 95: 125–32.

29. Karsh J: Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient. Drug Safety, 1990; 5: 317–27.

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)